Identification and characterisation of the novel amyloid-beta peptide-induced protein p17  by Nehar, Saheen et al.
FEBS Letters 583 (2009) 3247–3253journal homepage: www.FEBSLetters .orgIdentiﬁcation and characterisation of the novel amyloid-beta peptide-induced
protein p17
Saheen Nehar, Manisha Mishra, Klaus Heese *
Department of Molecular and Cell Biology, School of Biological Sciences, College of Science, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
a r t i c l e i n f o a b s t r a c tArticle history:
Received 9 July 2009
Revised 8 September 2009
Accepted 9 September 2009
Available online 13 September 2009






Neurotrophin0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.09.018
* Corresponding author. Fax: +65 6791 3856.
E-mail address: kheese@ntu.edu.sg (K. Heese).Amyloid-beta peptide (Ab) achieves neurodegeneration through unknown mechanisms. To eluci-
date some of these mechanisms, we conducted a cDNA subtraction analysis of Ab-mediated neuro-
toxicity in neuronal cells and observed an up-regulation of the novel gene p17. The p17 protein was
also found elevated in Alzheimer’s disease (AD) mouse model. Here, we characterised p17 primarily
in cell lines with respect to its localisation, function and physiological expression. We discovered
that p17 acts downstream of protein kinase C and inhibits the tyrosine receptor kinase B–brain-
derived neurotrophic factor (TrkB–BDNF) pathway. It impedes survival factors and enhances amy-
loid precursor protein expression thus suggesting its involvement in the Ab-mediated pro-apoptotic
pathways in AD.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that results in memory loss and cognitive dysfunctions.
Studies have established the two protein aggregates that are char-
acteristic of AD: extracellular amyloid plaques and intracellular
neruoﬁbrillary tangles (NFT) [1]. Irrefutable evidence from past
studies implies that amyloid-b peptides (Ab), the ‘building blocks’
of the amyloid plaques, contribute signiﬁcantly to the neurodegen-
eration in AD [2]. These peptides are derived from its precursor, the
amyloid precursor protein (APP) [3]. A mutation in this gene re-
sults in the aberrant production of the neurotoxic Ab [4]. However,
the pathways of which Ab achieves neurodegeneration are still
unknown.
As we aimed to elucidate some of these mechanisms, we ap-
plied the cDNA subtraction technique to Ab42 (contains 42 amino
acids)-induced B104 neuroblastoma cells [5]. This revealed several
novel genes that were differentially expressed. In this study, we re-
port the discovery of the novel pro-apoptotic protein p17 of which
the mRNA was signiﬁcantly up-regulated in Ab42-treated cells and
the protein level was remarkably increased in an AD mouse model
brain. Its physiological analysis in cell lines revealed that it is
downstream of protein kinase C (PKC). It promotes a pro-apoptotic
pathway via blocking the tyrosine receptor kinase B (TrkB) path-chemical Societies. Published by Eway causing a down-regulation in the key survival players, protein
kinase B (AKT) and extracellular regulated kinase 1/2 (ERK1/2). In
addition, p17 suppresses the anti-apoptotic functions of BCL-2.
Thus, we propose that p17 could be one of the mechanisms
through which Ab42 causes neurotoxicity in AD.2. Materials and methods
2.1. Reagents
All reagents used for experiments were purchased from Sigma–
Aldrich (Milwaukee, WI, USA) unless otherwise stated. The speciﬁc
PKC inhibitor bisindolylmaleimide GF109203X (Calbiochem, San
Diego, CA, USA) was used at varying concentrations (as indicated
in the text) to block PKC activity [6].
2.2. Cell culture and TrkB signaling analysis
A549 (human lung carcinoma), B104 (rat neuroblastoma), COS-
7 (African green monkey kidney), C2C12 (mouse myoblasts), CHO
(Chinese hamster ovary), HEK293T (human embryonic kidney),
H9C2 (2-1, rat heart myoblast), MCF-7 (human breast adenocarci-
noma), Mda-mb-231 (human breast adenocarcinoma), PC12 (rat
adrenal pheochromocytoma) and SH-SY5Y (human neuroblas-
toma) were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and maintained as described (Supple-
mentary materials and methods) [7–9] .lsevier B.V. All rights reserved.
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all-trans retinoic acid (RA) treatment for 48 h to increase TrkB
expression and a subsequent stimulation with 100 ng/ml of
BDNF (Peprotech, Rocky Hill, NJ, USA) for 48 h as described in
previous protocols [12,13]. BDNF-activated signaling pathways
were studied in B104 cells via an initial RA treatment as de-
scribed above. After 48 h, all media was aspirated and the
dishes were washed once with Dulbecco’s phosphate-buffered
saline (DPBS; Gibco, Invitrogen, Carlsbad, CA, USA) for serum re-
moval. Serum-free media was added and the cells were incu-
bated for 8 h at 37 C. Then, the cells were induced with
BDNF (100 ng/ml) for 15 min which was immediately followed
by an ice-cold DPBS wash. Cell lysis was performed as described
below.Fig. 1. Identiﬁcation of the novel protein, p17: Ab42-induced mRNA up-regulation, signi
was used to conﬁrm the cDNA subtraction analysis and demonstrate the up-regulation
control for mRNA input. (B) Western blot analysis of p17 protein in AD model and contro
Computational p17 protein sequence analysis revealed ﬁve phosphorylation sites of wh2.3. P17 transfection and p17 analysis
Cells were transfected using a lentivirus expression system (p17
in EF.CMV.GFP-Lenti-vector (ATCC); co-expression of p17 and the
green ﬂuorescent protein (GFP)) according to the manufacturer’s
protocol (Invitrogen) as brieﬂy described in Supplementary mate-
rials and methods.
P17 sub-cellular expression was studied using a p17 expression
construct that was generated by inserting the mouse p17 cDNA in-
frame with GFP (pcDNA3.1CT-GFP-TOPO, Invitrogen) at the C-ter-
minus of p17 (p17-CT-GFP). CHO cells were transiently transfected
with p17-CT-GFP, GFP (BD Biosciences, Clontech, Palo Alto, CA,
USA) expression vectors or empty plasmid (controls) using the
LipofectamineTM 2000 (Invitrogen) transfection reagent (accordingﬁcance of p17 in AD and p17 computational protein sequence analysis. (A) RT-PCR
of the p17 mRNA upon stimulation of B104 cells with Ab42. GAPDH was used as a
l WT brain lysates demonstrated that it was signiﬁcantly increased in AD model. (C)
ich two are phosphorylated by PKC.
Fig. 2. P17 expression in various mouse tissues and cell lines. (A) P17 mRNA was
analysed using the Rapid-ScanTM-Gene-Expression panels. P17 is ubiquitously
expressed in almost all tissues tested. 1 = heart; 2 = brain; 3 = kidney; 4 = liver;
5 = spleen; 6 = lung; 7 = pancreas; 8 = skeletal muscle. (B) Western blot analysis of
p17 protein in various mouse tissues showed that it was expressed predominantly
in the skeletal muscle, heart and lung. 1 = cerebellum; 2 = cortex; 3 = skeletal
muscle; 4 = olfactory bulb; 5 = kidney; 6 = liver; 7 = lung; 8 = heart; 9 = spleen. (C)
P17 protein expression analysis in various cell lines. 1 = MCF-7 (breast); 2 = Mda-
mb-231 (breast); 3 = COS-7 (kidney); 4 = HEK (kidney); 5 = H9C2 (heart); 6 = PC12
(adrenal medulla); 7 = C2C12 (muscle); 8 = A549 (lung); 9 = B104 (neural); 10 = cor-
tical neuron (neural). (D) Over-expression of p17 was conﬁrmed using p17-
transfected B104 and PC12 cells via Western blot. GFP-transfected cells were used
as controls: 1 = B104-GFP; 2 = B104-p17; 3 = PC12-GFP; 4 = PC12-p17.
S. Nehar et al. / FEBS Letters 583 (2009) 3247–3253 3249to the manufacturer’s protocol). The transfected cells were then
visualized using ﬂuorescence microscopy (Nikon TE2000S, Nikon,
Singapore) [14].
P17 cDNA and protein sequences analysis was conducted as de-
scribed previously (Supplementary materials and methods) [14].
2.4. cDNA subtraction, animal materials, Western blot,
immunocytochemistry (ICC) and immunohistochemistry (IHC)
PCR-Select-cDNA subtraction (Clontech, Mountview, CA, USA)
was performed, as described previously (Supplementary materials
and methods) [7]. The RNA extraction from human tissue and the
reverse transcription-polymerase chain reaction (RT-PCR) method
used for mRNA expression analyses were carried out as described
previously (Supplementary materials and methods) [7]. Rapid-
ScanTM-Gene-Expression panels (Origene Technologies, Rockville,
MD, USA) were purchased to check tissue-speciﬁc gene expression
of p17. The PCR samples were analysed in a 1.5% DNA electropho-
retic agarose E-gelTM (Invitrogen).
Mouse tissue and cortical neuron isolation was executed as de-
scribed previously (Supplementary materials and methods) [15].
Cell lysis was performed after the cells were washed with DPBS.
Protease inhibitor cocktail (1:25; Roche, Basel, Switzerland), phos-
phatase inhibitor-I (1:100) and phosphatase inhibitor-II cocktails
(1:100) were added into the cell lysis buffer that contains
150 mM NaCl, 5 mM ethylenediamine tetraacetic acid (EDTA), 1%
Triton X-100, 0.1% SDS. Lysed cells were triturated and centrifuged
at 10 000g at 4 C for 10 min. The supernatant was collected and
stored at 20 C. The Qproteome Cell Compartment Kit (Qiagen,
Düsseldorf, Germany) protocol was applied accordingly for H9C2
cell fractionation. SDS–PAGE andWestern blotting were performed
and the antibodies were used as described previously (Supplemen-
tary materials and methods) [15].
ICC and IHC were performed as described previously (Supple-
mentary materials and methods) [8,15].3. Results
3.1. Isolation of p17 and its signiﬁcance in AD
A cDNA subtraction analysis was performed comparing Ab42-
stimulated rat neuronal B104 cells (B104-Ab42) and control (un-
treated) cells. This revealed a novel mRNA, p17, markedly up-reg-
ulated in B104-Ab42 cells (Fig. 1A). The speciﬁc mRNA was isolated
via 50-RACE-RT-PCR. An AD mouse model was used to verify the
physiological presence and the signiﬁcance of p17 in AD (as de-
scribed in Supplementary materials and methods). We discovered
that the p17 protein was expressed in both control wild-type (WT)
and AD model brain lysates. However, p17 was markedly increased
in the AD model (Fig. 1B). The p17 protein sequence analysis re-
vealed potential PKC phosphorylation sites (Fig. 1C).
3.2. P17 expression in various tissues and cell lines
Using a Rapid-ScanTM-Gene-Expression panel, we found that
the p17 mRNA was ubiquitously present in various tissues
(Fig. 2A). We recognized that the p17 protein was particularly
highly expressed in heart, lung and skeletal muscle (Fig. 2B).
We also assessed the p17 protein expression in various cell lines
derived from diverse origins. This revealed that the heart-,
breast- and kidney-derived cell lines expressed high levels of
p17. The cortical neurons also expressed p17 copiously
(Fig. 2C). P17 was transfected into low endogenous p17-express-
ing cell lines, B104 and PC12, using a lentivirus expression sys-
tem, as described in Section 2, and checked for its over-expression. This revealed that p17 was abundantly over-ex-
pressed for further experiments. This also afﬁrmed the antibody’s
speciﬁcity to the p17 protein (Fig. 2D).
3.3. P17 localisation
We performed ICC on H9C2, a high endogenous p17-expressing
cell line, to determine p17 localisation. P17 protein expression pat-
tern was different in comparison to the cytoskeletal protein,
Vimentin, and the nucleus stain, DAPI (Fig. 3A). Then, we transfec-
ted CHO cells transiently with a p17-GFP fusion protein and visu-
alized under the ﬂuorescence microscope (as described in Section
2). This showed that p17 may be localised in either the membrane
or the cytosol but clearly not in the nucleus (Fig. 3B). As these re-
sults were not conclusive, H9C2 was subjected to cell fractionation.
Markers such as GAPDH and Vimentin were used to ensure a prop-
er performance of the fractionation. This conﬁrmed that p17 was
expressed in both the membrane and cytosol (Fig. 3C). We con-
ducted an immunohistochemical analysis of the WT mouse brain
for p17 protein expression and localisation. This revealed that it
was physiologically expressed in the hippocampus and cortex
(Fig. 3D).
3.4. P17 protein regulation by PKC and RA
We wanted to check if the differentiation of B104 cells would
alter the p17 protein expression. Hence, those cells were differen-
tiated using RA and BDNF according to previous reports [12,13].
This revealed that RA treatment alone increases the p17 protein
levels but the additional application of BDNF did not further affect
the expression (Fig. 4A).
3250 S. Nehar et al. / FEBS Letters 583 (2009) 3247–3253In the cell line analysis for p17 protein expression, we real-
ized that the two human breast cell lines expressed p17 con-
versely. Mda-mb-231 expressed p17 copiously but MCF-7 had
no p17 expression (Fig. 2C). Further investigations led us to dis-
cover that MCF-7 has low PKC activity meanwhile Mda-mb-231
exhibits high PKC activity [16,17]. The involvement of PKC was
also implicated from the sequence analysis (Fig. 1B). Therefore,
we used GF109203X, a potent PKC-speciﬁc inhibitor [6], to sup-
press the PKC activity in Mda-Mb-231, Mcf-7, H9C2 cells
(Fig. 4B). H9C2 was included in this experiment due to its high
p17 expression. The PKC activity inhibition led to a signiﬁcantFig. 3. Intracellular and immunohistochemical localisation of p17. (A) H9C2 immuno
(cytoskeleton) and DAPI (nucleus) staining (scale bar: 50 lm). (B) A p17-GFP fusion pro
membrane localisation (scale bar: 50 lm). (C) Cell fractionation was performed with H
expressed in cytosol and membrane fractions. 1 = cytosol; 2 = membrane; 3 = nucleus;
mouse brain revealed that p17 is expressed in the hippocampus (a = CA1 region;
cortex = 500 lm and a, b, c, d = 100 lm.decrease in p17 expression in H9C2 and Mda-Mb-231 in a dose
dependent manner. This ﬁnding suggests that p17 is downstream
of PKC action and PKC involvement appears to be essential for its
expression.
3.5. P17 promotes a pro-apoptotic pathway
We examined the effect of p17 over-expression on the TrkB–
BDNF signaling pathway and found that B104-GFP cells exhibited
TrkB phosphorylation upon BDNF stimulation while B104-p17 ex-
pressed no such effect (Fig. 5).cytochemistry showed that p17 expression pattern was different from Vimentin
tein was transiently expressed in CHO cells and visualized indicating its cytosol or
9C2 cells and was subjected to Western blot analysis. This showed that p17 was
4 = cytoskeleton; 5 = H9C2 total lysate. (D) Immunohistochemical analysis of WT
b = dentate gyrus; c = CA3 region) and cortex (d). Scale bar: hippocampus and
Fig. 4. The p17 protein is up-regulated by RA and it acts downstream of PKC. (A) Differentiated B104 cells, when subjected to Western blot analysis, showed that the addition
of RA increased p17 expression. 1 = B104 control; 2 = B104 + RA (96 h); 3 = B104 + RA (96 h) + BDNF (48 h). (B) Speciﬁc PKC inhibition by GF109203X (GF) for 48 h led to a
decrease in p17 protein in a dose dependent manner. 1 = MCF-7; 2 = MCF-7 + 0.5 lM GF; 3 = MCF-7 + 1 lM GF; 4 = Mda-mb-231; 5 = Mda-mb-231 + 0.5 lM GF; 6 = Mda-mb-
231 + 1 lM GF; 7 = H9C2; 8 = H9C2 + 0.5 lM GF; 9 = H9C2 + 1 lM GF.
Fig. 5. P17 promotes a pro-apoptotic pathway. GFP (mock-)- and p17-transfected
B104 cells were compared and analysed using Western blot. While the BDNF-
mediated TrkB phosphorylation was inhibited by p17, the activation (phosphory-
lation) of AKT and ERK were also heavily down-regulated in B104-p17 cells. In
contrast, the phosphorylation of BCL-2 was signiﬁcantly enhanced.
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monly affected in AD and neuronal survival. This revealed an en-
hanced expression of APP and its phosphorylated form in B104-
p17 cells in comparison to control B104-GFP cells. The active forms
of the survival kinases, AKT and ERK1/2, were signiﬁcantly de-
creased in B104-p17 cells. A decrease in ERK was also observedin B104-p17 cells. Interestingly, the BCL-2 protein was signiﬁcantly
phosphorylated in B104-p17 cells at the sites Ser70 and Thr56.4. Discussion
In the present study we report the ﬁnding of a novel protein,
p17, of which the neuronal mRNA expression was signiﬁcantly in-
creased in B104-Ab42. In the AD mouse model, p17 protein expres-
sion was considerably enhanced in the brain tissue. Its expression
was particularly pronounced in the lung and heart tissues in com-
parison to the brain. These ﬁndings suggest that p17 may not be
physiologically expressed much under normal conditions in the
brain but, as a potential pro-apoptotic protein, is up-regulated un-
der pathological conditions such as Ab42 treatment in B104 cells
and in AD.
We determined the physiological function of p17 and its effect
on the AD-related signaling pathways (Fig. 6). Our results clearly
illustrate that p17 is a pro-apoptotic protein. An enhanced expres-
sion of APP and its phosphorylated form is caused by the over-
expression of p17 (Fig. 5). Over-expression of APP has been shown
to result in amyloidogenic Ab formations [18,19]. Thus, p17 may
play a role in the accumulation of Ab via elevating APP expression
during AD pathogenesis. P17 also exempliﬁed its pro-apoptotic
nature by inhibiting the activation of the TrkB receptor by BDNF.
This interaction is crucial for memory processes and survival of
neurons which are speciﬁcally affected in AD [20–23]. Ab also
hampers the BDNF functions via decreasing the activity of the TrkB
receptor [20]. P17 may serve as one of the mechanisms through
which Ab uses to achieve this inhibitory effect. P17 also caused a
signiﬁcant decrease in the activity of the well established pro-sur-
vival kinases such as AKT and ERK which are downstream to the
TrkB/BDNF transduction pathway [24,25]. These kinases, however,
were down-regulated even prior to BDNF stimulation. This reveals
that the p17 not only inhibits the BDNF/TrkB transduction but also
directly inhibits these pro-survival kinases. The BCL-2 protein is a
well recognized anti-apoptotic protein. However, it was phosphor-
ylated at two different sites, Ser70 and Thr56, in p17 over-express-
ing cells thus again exhibiting pro-apoptotic signaling of p17 as
past studies have shown that BCL-2 expresses its anti-apoptotic
nature only when it’s phosphorylated at a single site at Ser70
[26,27] but multi-site phosphorylations have been shown to inac-
tivate the anti-apoptotic protein instead [26–28]. The Thr56 phos-
phorylation inhibits the anti-apoptotic BCL-2 activity when
phosphorylations at other sites are also present [29]. Consequently,
p17 represses the anti-apoptotic character of BCL-2 by phosphory-
lating the protein at Thr56 and Ser70.
PKC is a multifaceted kinase that plays a wide range of roles in
apoptosis and cell survival [30]. Its activation leads to a decrease in
secreted Ab [31]. Despite of its effects on cell survival, the over-
expression of PKC has shown to induce excitotoxicity in neurons
[30]. Our results indicate that PKC may induce p17 in response to
Ab stimulation to cause neurotoxicity.
Fig. 6. P17 promotes a pro-apoptotic pathway. P17 inhibits AKT, ERK and the TrkB transduction pathway denoted by the red lines. This affects the neuronal survival
pathways. P17 is also involved in phosphorylating BCL-2 at two different sites, Ser70 and Thr56, causing a suppression of its anti-apoptotic character.
3252 S. Nehar et al. / FEBS Letters 583 (2009) 3247–3253Ab peptide-induced neurotoxicity has been strongly implicated in
AD [2,32]. However, the pathogenicmechanisms behind this peptide
are still widely unknown [32]. Our current study provides an addi-
tional possible mechanism, the induction of p17, through which Ab
acts to induce apoptosis and exhibit other AD characteristics. As
the p17 protein levels are less pronounced in WT brain and are ele-
vated under neuropathological conditions, it appears that the protein
may play an anomalous role in the brain. Expounding the pathway of
this protein has also exposed p17’s pro-apoptotic character. The evi-
dence gained on this protein suggests that it aids the Ab peptide-in-
duced apoptosis. However, more extensive research is necessary to
further characterise the physiological role of p17 and more impor-
tantly its role in neurodegenerative processes related to AD.
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